George Thomas, DO
Family Medicine · Meridian, IDNPI 1972540870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$779
- AstraZeneca$691
- Pfizer$651
- Novo Nordisk$601
- Lilly USA, LLC$350
- Boehringer Ingelheim$273
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,104100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $779 |
| AstraZeneca | 35 | $691 |
| Pfizer | 44 | $651 |
| Novo Nordisk | 36 | $601 |
| Lilly USA, LLC | 23 | $350 |
| Boehringer Ingelheim | 12 | $273 |
| Teva Pharmaceuticals USA, Inc. | 12 | $230 |
| Astellas Pharma US Inc | 8 | $193 |
| Johnson & Johnson | 13 | $192 |
| Amgen | 10 | $191 |
| Corcept Therapeutics | 9 | $166 |
| Dexcom, Inc. | 6 | $158 |
| GSK | 8 | $151 |
| Bayer | 8 | $131 |
| Novartis | 7 | $126 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $115 |
| Abbott | 6 | $113 |
| Exact Sciences | 5 | $99 |
| Antares Pharma, Inc. | 5 | $90 |
| Exeltis, USA Inc. | 5 | $71 |
| Merck | 5 | $71 |
| Shield Therapeutics Inc | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $64 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Lucid Diagnostics Inc. | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 3 | $43 |
| Mylan Specialty L.p. | 2 | $41 |
| Mayne Pharma Commercial LLC | 2 | $39 |
| Halozyme Inc | 2 | $36 |
| Genentech USA, Inc. | 2 | $35 |
| Viatris Specialty LLC | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Organon | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Coloplast | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $11 |
How this compares
$6,104 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $101,111 |
| FarxigaDapagliflozin Propanediol | 72 | $84,041 |
| EliquisApixaban | 40 | $52,139 |
| JardianceEmpagliflozin | 18 | $31,525 |
| MounjaroTirzepatide | 17 | $30,063 |
| Bydureon BciseExenatide Microspheres | 18 | $23,659 |
| XareltoRivaroxaban | 19 | $21,621 |
| Fluticasone Propionate HfaFluticasone Propionate | 15 | $6,759 |
| Atorvastatin Calcium | 570 | $5,186 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $4,591 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,199 |
| Gabapentin | 115 | $3,612 |
| Omeprazole | 221 | $3,482 |
| Metoprolol Succinate | 199 | $2,553 |
| Levothyroxine Sodium | 263 | $2,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $601 | $101,11169 claims |
| AstraZenecaFarxiga | $691 | $84,04172 claims |
| PfizerEliquis | $651 | $52,13940 claims |
| Boehringer IngelheimJardiance | $273 | $31,52518 claims |
| Lilly USA, LLCMounjaro | $350 | $30,06317 claims |
| Johnson & JohnsonXarelto | $192 | $21,62119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.
Other family medicine in Meridian
- David ButukMeridian$206K
- Timothy McHughMeridian$165K
- Mark JohnsonMeridian$10K
- Jason LudwigMeridian$7K
- Jacob SmithMeridian$7K
- Ginger AllenMeridian$6K
- Mark TurnerMeridian$6K
- Aaron MoorhouseMeridian$5K
- Kenneth CongerSandpoint$266K
- Anne BroadwayIdaho Falls$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.